Genmab Trial Reports 50% Lower Risk of Death in Interim Analysis
The petosemtamab and pembrolizumab combination met both primary endpoints in a Phase 3 trial of PD-L1-positive head and neck cancer.
Makkler Newsroom · Oct 29, 03:07 AM · 1 min read
Market closed· · DKK · Data may be delayed
Avg. target DKK 4,394.70 (+25.5%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO